Blunted Thrombopoietin Response to Interferon Alfa-Induced Thrombocytopenia During Treatment for Hepatitis C
Open Access
- 1 November 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 28 (5) , 1424-1429
Abstract
Thrombocytopenia is common in advanced–stage liver disease and is partly caused by inadequate thrombopoietin (TPO) production in the failing liver. Treatment of chronic hepatitis C with interferon alfa (IFN–α) often induces thrombocytopenia, sometimes even leading to discontinuation of treatment. TPO regulation in response to IFN–α-induced thrombocytopenia was studied in patients with chronic hepatitis C with and without cirrhosis (Child A). An in vitro culture system with HepG2 cells was used to demonstrate any direct effects of IFN–α on TPO mRNA expression, TPO synthesis, or TPO secretion from liver cells. Thrombocyte count was lower (U test: P < .05) in patients with hepatitis C cirrhosis compared with patients with chronic hepatitis C without cirrhosis before IFN therapy, and decreased in both patient groups (Wilcoxon matched–pairs test: P < .05) on IFN therapy, the median decrease in both groups being comparable (noncirrhotic patients, 35%; cirrhotic patients, 32%; U test: P = .57). TPO levels rose in noncirrhotic patients (Wilcoxon matched–pairs test: P < .05), but not in patients with cirrhosis (noncirrhotic patients' median increase: 43% vs. cirrhotic patients' median decrease: 5%; U test: P < .001). Even in patients without cirrhosis, the increase in TPO levels was relatively small for the decrease in platelet count. No effect of IFN–α could be demonstrated on TPO mRNA expression in vitro, but TPO secretion from liver cells was significantly reduced. Lower platelet counts but similar TPO levels in patients with chronic hepatitis C and cirrhosis compared with noncirrhotic patients and a moderate increase in TPO levels in noncirrhotic patients with a missing increase in cirrhotic patients during IFN–α-induced thrombocytopenia provide further evidence for an impairment of TPO production in patients with cirrhosis and during IFN therapy. Recombinant human TPO could be of value in patients developing severe thrombocytopenia under IFN–α therapy.Keywords
This publication has 27 references indexed in Scilit:
- Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?Journal of Hepatology, 1997
- The Treatment of Chronic Viral HepatitisNew England Journal of Medicine, 1997
- Dose increase augments response rate to interferon-α in chronic hepatitis CDigestive Diseases and Sciences, 1996
- Risks and Benefits of Interferon-α in the Treatment of HepatitisDrug Safety, 1995
- A Comparison of Three Interferon Alfa-2b Regimens for the Long-Term Treatment of Chronic Non-A, Non-B HepatitisNew England Journal of Medicine, 1995
- Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development.Proceedings of the National Academy of Sciences, 1995
- Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligandNature, 1994
- Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis BAnnals of Internal Medicine, 1993
- Thrombocytopenia during interferon alfa therapyJAMA, 1991
- Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2The American Journal of Medicine, 1984